✦ LIBER ✦

Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2

✍ Scribed by Flavio Arienti; Filiberto Belli; Licia Rivoltini; Carlo Gambacorti-Passerini; Luigi Furlan; Luigi Mascheroni; Augusto Prada; Maurilia Rizzi; Edoardo Marchesi; Maurizio Vaglini; Giorgio Parmiani; Natale Cascinelli

Publisher: Springer-Verlag
Year: 1993
Tongue: English
Weight: 890 KB
Volume: 36
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf01741170

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical efficacy of adoptive immunother

Clinical efficacy of adoptive immunotherapy by IL-4 activated tumor-infiltrating lymphocytes in patients with advanced cancer

✍ Takuya Tsunoda; Hiroshi Tanimura; Hiroki Yamaue; Makoto Iwahashi; Masaji Tani; K 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 491 KB

Adjuvant adoptive immunotherapy with tum

Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients

✍ R. Ridolfi; Emanuela Flamini; Angela Riccobon; F. De Paola; Roberta Maltoni; A. 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 184 KB

A randomized trial of adoptive immunothe

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer

✍ Giovanni B. Ratto; Paolo Zino; Sandro Mirabelli; Paolo Minuti; Riccardo Aquilina 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 750 KB

A previous pilot study from our group suggested that: (1) adoptive immunotherapy (AI) with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2) may be applied with safety to more than 80% of the patients who had surgery for Stage 111 nonsmall cell lung carcinoma (NSCLC); and (2

Long-term immunotherapy with low-dose in

Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma

✍ Carlo Buzio; Simeone Andrulli; Rosaria Santi; Laura Pavone; Rodolfo Passalacqua; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Stimulation of natural killer activity i

Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2

✍ Markus G. Seidel; Michael Freissmuth; Hubert Pehamberger; Michael Micksche 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 148 KB

Phase I/II study of treatment with matur

Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

✍ P. Hersey; G. M. Halliday; M. L. Farrelly; C. DeSilva; M. Lett; S. W. Menzies 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 577 KB